

1 **Negeviruses reduce replication of alphaviruses during co-infection**

2

3 Edward I. Patterson<sup>1,2,3\*</sup>, Tiffany F. Kautz<sup>1†</sup>, Maria A. Contreras-Gutierrez<sup>1,4,5</sup>, Hilda

4 Guzman<sup>1</sup>, Robert B. Tesh<sup>1</sup>, Grant L. Hughes<sup>2</sup>, Naomi L. Forrester<sup>1,6</sup>

5

6 <sup>1</sup> Department of Pathology, University of Texas Medical Branch, Galveston, TX

7 77550, USA

8 <sup>2</sup> Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected

9 Tropical Disease, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK

10 <sup>3</sup> Department of Biological Sciences, Brock University, St. Catharines, ON L2S 3A1,

11 Canada

12 <sup>4</sup> Tecnológico de Antioquia, Institución Universitaria, Medellin, Colombia

13 <sup>5</sup> Grupo de Investigación en Sistemática Molecular, Universidad Nacional de

14 Colombia, Medellin, Colombia

15 <sup>6</sup> School of Life Sciences, University of Keele, Keele ST5 5BG, UK

16 † Current address: Glenn Biggs Institute for Alzheimer's and Neurodegenerative

17 Diseases, UT Health San Antonio, San Antonio, TX 78229, USA

18 \* Corresponding author: [ipatterson@brocku.ca](mailto:ipatterson@brocku.ca)

19 **Abstract**

20           Negevirus are a group of insect-specific virus (ISV) that have been found in  
21 many arthropods. Their presence in important vector species led us to examine  
22 their interactions with arboviruses during co-infections. Wild-type negevirus  
23 reduced the replication of several alphaviruses during co-infections in mosquito  
24 cells. Negevirus (NEGV) isolates were also used to express GFP and anti-  
25 chikungunya virus (CHIKV) antibody fragments during co-infections with CHIKV.  
26 NEGV expressing anti-CHIKV antibody fragments was able to further reduce  
27 replication of CHIKV during co-infections, while reductions of CHIKV with NEGV  
28 expressing GFP were similar to titers with wild-type NEGV alone. These results are  
29 the first to show that negevirus induce superinfection exclusion of arboviruses  
30 and to demonstrate a novel approach to deliver anti-viral antibody fragments with  
31 paratransgenic ISVs. The ability to inhibit arbovirus replication and express  
32 exogenous proteins in mosquito cells make negevirus a promising platform for  
33 control of arthropod-borne pathogens.

34

35 **Importance**

36           Negevirus are a group of insect-specific viruses (ISVs), viruses known to  
37 only infect insects. They have been discovered over a wide geographical and species  
38 range. Their ability to infect mosquito species that transmit dangerous arboviruses  
39 makes negevirus a candidate for a pathogen control platform. Co-infections of  
40 mosquito cells with a negevirus and an alphavirus demonstrated that negevirus  
41 can inhibit the replication of alphaviruses. Additionally, modifying Negevirus

42 (NEGV) to express a fragment of an anti-CHIKV antibody further reduced the  
43 replication of CHIKV in co-infected cells. This is the first evidence to demonstrate  
44 that negevirus can inhibit the replication of important arboviruses in mosquito  
45 cells. The ability of a modified NEGV to drive the expression of antiviral proteins  
46 also highlights a method for negevirus to target specific pathogens and limit the  
47 incidence of vector borne diseases.

48 **Introduction**

49 Many insect-specific viruses (ISVs) have been discovered in wild-caught and  
50 laboratory colonies of mosquitoes and in mosquito cell cultures (1). ISVs are only  
51 known to replicate in arthropods or insect cell lines. While posing no threat to  
52 human or animal health, ISVs may affect the transmission of more dangerous  
53 vector-borne pathogens. Highly insect-pathogenic ISVs have been suggested for use  
54 as biological control agents to reduce populations of vector competent mosquitoes  
55 (2-4). Several recent studies have demonstrated that ISVs may play a more direct  
56 role by inhibiting the replication of arboviruses within the insect host. The majority  
57 of these experiments have attempted to define a relationship based on  
58 superinfection exclusion, a phenomenon in which an established virus infection  
59 interferes with a secondary infection by a closely related virus. For example, insect-  
60 specific flaviviruses, such as cell fusing agent virus (CFAV), Nhumirim virus (NHUV)  
61 and Palm Creek virus (PCV) have demonstrated an ability to reduce viral loads of  
62 vertebrate pathogenic flaviviruses, like West Nile virus (WNV), Zika virus (ZIKV),  
63 dengue virus (DENV), Japanese (JEV) and St. Louis encephalitis (SLEV) viruses (5-  
64 10). Similarly, the insect-specific alphavirus Eilat virus (EILV) was shown to reduce  
65 or slow replication of the pathogenic alphaviruses chikungunya virus (CHIKV),  
66 Sindbis virus (SINV), eastern (EEEV), western (WEEV) and Venezuelan equine  
67 encephalitis (VEEV) viruses in cell culture or in mosquitoes (11). Less information is  
68 available about the effect of unrelated viruses during superinfection. Cell cultures  
69 chronically infected with *Aedes albopictus* densovirus (AalDENV) limit replication of  
70 DENV (12), cell cultures with established CFAV and Phasi Charoen-like virus (PCLV)

71 infections reduced ZIKV and DENV replication (13), and co-infections with Yichang  
72 virus, a mesonivirus, reduced DENV replication in cells and dissemination in  
73 mosquitoes (14). The mechanism for these reduced titers has not been elucidated,  
74 but the relationships appear to be virus specific and even host specific (5, 15, 16).

75         The genus *Negevirus* is a recently discovered, unclassified group of ISVs (17).  
76 Members of this genus have been isolated from several species of hematophagous  
77 mosquitoes and sandflies, and negev-like viruses have also been found in other non-  
78 vector insects (18-25). Phylogenetic studies have placed this group of viruses most  
79 closely to members of the genus *Cilevirus*, plant pathogens that are transmitted by  
80 mites (17, 24). These viruses have a single-stranded, positive-sense RNA genome of  
81 ~9-10 kb, and contain three open reading frames (ORFs) (17). The ORFs encode for  
82 the replication machinery (ORF1), a putative glycoprotein (ORF2), and a putative  
83 membrane protein (ORF3). Electron microscopy has shown the structural proteins  
84 to be arranged in a hot air balloon morphology, a round particle with a single  
85 protrusion that is likely the glycoprotein structure (26-28). Little is known about  
86 the infectivity, transmission dynamics, and species range of negeviruses. However,  
87 they are commonly found in field collected mosquitoes (29, 30).

88         The association of negeviruses with important vector species over a wide  
89 geographical range raises the question of possible interactions or interference of  
90 negeviruses with vertebrate pathogenic viruses. Few studies exist that demonstrate  
91 the ability of unrelated viruses to induce superinfection exclusion, but evidence for  
92 this phenomenon with negeviruses could provide a platform to control vector-borne  
93 viral diseases in many arthropod vector species. In this study, three negevirus

94 isolates from the Americas were assessed for superinfection exclusion in cell  
95 cultures with VEEV, CHIKV Mayaro virus (MAYV), o'nyong'nyong virus (ONNV), and  
96 Semliki Forest virus (SFV). The use of a Negev virus (NEGV) infectious clone also  
97 allowed manipulation of the virus genome to provide a greater ability to exclude  
98 superinfection with CHIKV.

99

## 100 **Results**

### 101 *Wild-type negevirus growth curves*

102 All wild-type negeviruses reached titers greater than  $10\log_{10}$  pfu/mL within  
103 48 hours when infected at a MOI of 1 (Figure 1A). NEGV and PIUV-Lutzomyia neared  
104 peak titer by 12 hours post infection (hpi), while PIUV-Culex neared peak titer at 24  
105 hpi. Infections of NEGV with MOIs of 1 and 5 produced similar growth curves  
106 (Figure 1B).

107

### 108 *Superinfection exclusion of alphaviruses with wild-type negeviruses*

109 To determine the effect of negeviruses on the replication of alphaviruses in  
110 cell culture, negevirus isolates were co-infected with VEEV-TC83 or CHIKV isolates.  
111 NEGV was able to significantly reduce replication of VEEV-TC83, with reductions of  
112 5.5-7.0  $\log_{10}$  pfu/mL of VEEV at 48 hours (Figure 2A). There were no significant  
113 differences in VEEV-TC83 titers when co-infected with NEGV inoculated at MOIs of 1  
114 or 5. There were also no significant differences in VEEV-TC83 titer when NEGV  
115 inoculation preceded VEEV-TC83 inoculation by 0-, 2- or 6 hours. Co-infection with  
116 PIUV-Culex or PIUV-Lutzomyia also significantly reduced replication of VEEV-TC83

117 across all time points (Figure 2B-D). A similar reduction of VEEV-TC83 was  
118 observed during all negevirus co-infections, as VEEV-TC83 was reduced 4.6-7.2  
119  $\log_{10}$  pfu/mL at 48 hours.

120 Co-infections with CHIKV and NEGV also resulted in significantly lower titers  
121 of CHIKV at all time points, but only reducing the titer of CHIKV by 0.65-0.93  $\log_{10}$   
122 pfu/mL after 48 hours (Figure 3A). Varying the MOI of NEGV and timing of CHIKV  
123 inoculation only produced differing titers of CHIKV at the 12-hour timepoint.  
124 However, titers of CHIKV during co-infection with different negeviruses varied  
125 greatly (Figure 3B, C), with the largest variance of CHIKV titers, reductions of 0.7  
126  $\log_{10}$ , 2.4  $\log_{10}$  and 5.3  $\log_{10}$  pfu/mL, observed when inoculated 6 hours post-  
127 inoculation with NEGV, -PIUV-Culex and -PIUV-Lutzomyia, respectively (Figure 3D).

128 NEGV and PIUV-Lutzomyia were also able to reduce replication of several  
129 other alphavirus isolates by varying amounts when infected simultaneously. Titers  
130 of VEEV-IC were reduced by 2.8-3.0  $\log_{10}$  pfu/mL at 48 hours post co-infection  
131 (Figure 4A). Three isolates of MAYV, Guyane, BeAn343102, and BeAr505411, were  
132 reduced by 1.9-3.2  $\log_{10}$  pfu/mL at 48 hours post co-infection (Figure 4B). Outputs  
133 between MAYV co-infections were similar with significant differences at 48 hours  
134 only seen between MAYV-Guyane co-infected with NEGV and PIUV-Lutzomyia,  
135 respectively. ONNV titers were reduced by 2.4-3.2  $\log_{10}$  pfu/mL, and SFV was  
136 reduced by 1.2-1.8  $\log_{10}$  pfu/mL after 48 hours (Figure 4C, D).

137

138 *Replication of modified NEGV isolates*

139           The sequence for GFP was successfully cloned as both a fusion- and cleaved  
140 protein at several sites along the NEGV infectious clone (Table 1, Figure 5A).  
141 Following electroporation, viable virus was rescued from isolates with GFP inserted  
142 as a fusion- and cleaved protein on the C-terminal of ORF3, and as a cleaved protein  
143 on the C-terminal of ORF1.

144           Further experiments used isolates with GFP added to the ORF3 (NEGV GFP-  
145 fusion and NEGV GFP) and also with GFP swapped with scFv CHK265, a partial  
146 sequence for an anti-CHIKV antibody (Figure 5A). Mutated isolates were rescued  
147 and had titers ranging from 9.6-10.4 log<sub>10</sub> pfu/mL, with similar growth curves to the  
148 wild-type NEGV (Figure 5B). Cells infected with NEGV GFP-fusion demonstrated  
149 brilliant, punctate fluorescence (Figure 5C), while cells infected with NEGV GFP  
150 (cleaved) demonstrated dull, diffuse fluorescence (Figure 5D). The number of  
151 fluorescent plaques and overall titer of NEGV isolates expressing GFP remained  
152 stable for 5 passages in C7/10 cells (Figure 5E, F).

153

#### 154 *Superinfection exclusion of alphaviruses with modified NEGV*

155           NEGV isolates expressing GFP or scFv-CHK265 were used to infect cells for  
156 co-infection with VEEV-TC83 or CHIKV. The results for co-infections with VEEV-  
157 TC83 were similar to the reduction in titer seen with wild-type viruses. At the 48-  
158 hour timepoint, VEEV-TC83 was reduced by 4.5-5.5 log<sub>10</sub> pfu/mL when co-infected  
159 with NEGV isolates (Figure 6A), 4.6-5.8 log<sub>10</sub> pfu/mL when infected 2 hours post  
160 NEGV isolates (Figure 6B), and 5.6-6.9 log<sub>10</sub> pfu/mL when infected 6 hours post  
161 NEGV isolates (Figure 6C). When infected simultaneously with CHIKV, titers were

162 reduced by 0.7-1.1 log<sub>10</sub> pfu/mL during co-infections of NEGV expressing GFP, and  
163 by 2.9-3.8 log<sub>10</sub> pfu/mL during co-infections of NEGV expressing scFv-CHK265 at the  
164 48-hour timepoint (Figure 7A). When inoculated 2 hours post NEGV infection, the  
165 titer of CHIKV after 48 hours was reduced 0.7-0.9 log<sub>10</sub> pfu/mL with NEGV  
166 expressing GFP and 3.7-4.5 log<sub>10</sub> pfu/mL with NEGV expressing scFv-CHK265  
167 (Figure 7B). Delaying CHIKV infection 6 hours post NEGV resulted in reductions of  
168 1.2-1.9 log<sub>10</sub> pfu/mL and 5.2-5.7 log<sub>10</sub> pfu/mL after 48 hours of co-infection with  
169 NEGV expressing GFP and scFv-CHK265, respectively (Figure 7C).

170

## 171 **Discussion**

172 The microbiome of arthropod vectors is known to influence host-pathogen  
173 interactions (31-33). The precise mechanisms of pathogen inhibition are unknown,  
174 but there is increasing evidence that interference from ISVs is one mechanism (5-7,  
175 10). Interactions between related viruses has led to the theory of superinfection  
176 exclusion, in which an established infection interferes with or inhibits a secondary  
177 infection by a closely related virus. For example, a CFAV mosquito isolate reduced  
178 the replication of DENV and ZIKV during co-infections in mosquitoes and mosquito  
179 cells (5).

180 To investigate if superinfection exclusion occurred with other virus  
181 combinations, pathogenic alphaviruses and negevirus were used in co-infection  
182 experiments. Titers of multiple VEEV isolates and MAYV isolates were consistently  
183 reduced during co-infection experiments with negevirus. Reductions varied  
184 during CHIKV-negevirus co-infections. These results provide further evidence that

185 superinfection exclusion of alphaviruses is pathogen specific, but differ from a  
186 previous report demonstrating no reduction in titer of VEEV TC-83 and a significant  
187 reduction of wild-type VEEV-IC (strain 3908) after 48 hours when co-infected with  
188 EILV, an alphavirus ISV (11). However, the potential for superinfection exclusion of  
189 pathogens is different for each ISV, despite their relatedness. These differences have  
190 been demonstrated among several insect-specific flaviviruses, Nhumirim virus  
191 (NHUV) and Palm Creek virus (PCV) were capable of superinfection exclusion; CFAV  
192 gave varying results; and Culex flavivirus (CxFV) did not reduce titers of pathogenic  
193 arboviruses (5-10, 15, 16, 34-37). In our experiments with negevirus, PIUV  
194 isolates were more capable than NEGV at inhibiting important arboviruses.

195         While ISVs show promising results to block arbovirus replication in  
196 mosquito vectors, their unknown mechanism of action may limit their use against a  
197 wide range of pathogens, but paratransgenic ISVs could be used to provide antiviral  
198 molecules that specifically interfere with pathogen transmission (38). To this end,  
199 we used an infectious clone of NEGV to deliver a fragment of an antibody known to  
200 neutralize CHIKV (39). A scFv consists of the variable regions of the heavy and light  
201 chains of an antibody, joined by a soluble linker. These antibody fragments can  
202 possess the neutralizing qualities of their full-size versions in only ~27kDa. Co-  
203 infections with scFv-expressing NEGV isolates greatly reduced titers of CHIKV,  
204 whereas co-infections with control NEGV isolates expressing GFP or wild-type NEGV  
205 only modestly reduced CHIKV titers. The use of parastransgenic NEGV expressing  
206 scFvs demonstrates a novel approach to disrupt pathogen infection in mosquitoes.  
207 This method adapts two existing techniques for pathogen control: *Wolbachia*

208 infected mosquitoes and the CRISPR-Cas-aided integration of scFv sequences into  
209 the mosquito genome. *Wolbachia* is a ubiquitous species of bacteria found in many  
210 insects that has been shown to block replication of some viral pathogens in cell  
211 cultures and mosquitoes. The use of *Wolbachia*-infected vectors has been widely  
212 adapted to curb mosquito-borne viral diseases, propelled by its natural ability to  
213 colonize mosquitoes (40). Negevirus also possess this attribute, having been  
214 discovered in numerous mosquito species on 6 continents, along with sandflies and  
215 other diverse insect species (20-23, 25). Insertion of gene-editing scFv sequences  
216 into mosquito genomes has also been used to prevent *Plasmodium* and DENV  
217 infection (41, 42). By using CRISPR-Cas9 to insert a scFv targeting *Plasmodium*,  
218 infection was blocked in *Anopheles* mosquitoes, and gene drive ensured the  
219 production of the scFv in the offspring. In this study, we used scFv expression  
220 strategy by cloning an anti-CHIKV scFv into the NEGV genome. Using NEGV as a  
221 vehicle for paratransgenesis is advantageous, because an isolate can infect multiple  
222 host species, and it is suspected to be vertically transmitted in mosquitoes and in  
223 theory could become established in multiple generations of the infected host species  
224 (17, 22, 43).

225         Modifications to certain parts of the NEGV genome were tolerated as both  
226 cleaved and fusion proteins. Expression of extraneous proteins in viruses is  
227 common with 2A sequences to produce separate proteins or under a separate  
228 subgenomic promoter (44, 45). However, extraneous proteins expressed as a fusion  
229 with a structural virus protein is uncommon. ORF3 is ~25kDa and is suspected to be  
230 the membrane protein, the dominant structural protein; and ORF2 is ~40kDa and is

231 the putative glycoprotein predicted to form a bud projecting from one end of the  
232 virion (26). The viability of the NEGV isolates with GFP- or scFv-fusion at ORF3  
233 isolates was surprising because these inserts double the size of the membrane  
234 protein, which must interact with itself and ultimately support the projection of the  
235 glycoprotein. The modifications to ORF2 resulting in non-viable virus are not  
236 surprising as the glycoprotein is suggested to be important for cell attachment and  
237 entry (26). GFP preceded by a 2A sequence was also successfully cloned onto the C-  
238 terminal of ORF1. As 2A allows for separation of the two proteins, this insertion only  
239 added 17 residues to a ~268kDa protein. However, ORF1 will likely be expressed at  
240 lower levels compared to ORF3. By using NEGV to express anti-CHIKV scFvs, the  
241 cleaved and fused inserts may provide distinct advantages. Cleaved scFvs are free to  
242 be transported around the cell, accessing many different locations where they may  
243 encounter CHIKV proteins. In contrast, fused proteins are bound to the membrane  
244 protein of NEGV and are limited to compartments of the cell where NEGV proteins  
245 are expressed, and virions are assembled. In theory, increasing the concentration of  
246 the scFvs in specific areas of the cell, should inhibit CHIKV virion assembly and  
247 egression. By using both cleaved and fused NEGV isolates, the scFv sequence can  
248 also be easily replaced to target a new pathogen, adding to the versatility of this  
249 technique.

250         The current experiments demonstrate the ability of some negevirus, both  
251 wild-type and paratransgenic isolates, to inhibit the replication in mosquito cells  
252 with co-infected arboviruses. The next question is whether genetically altered  
253 negevirus will survive and replicate in live mosquitoes; and if so, will they be

254 vertically transmitted or transovarially transmitted in the insects? This will be our  
255 next area of investigation. If successful, then the use of paratransgenic negevirus  
256 could be another novel method to alter the vector competence of mosquitoes for  
257 selected arboviruses.

258

## 259 **Materials and Methods**

### 260 *Cell culture and viruses*

261 *Aedes albopictus* (C7/10) cells (46) were obtained from the World Reference  
262 Center for Emerging Viruses and Arboviruses (WRCEVA). African green monkey  
263 kidney (Vero E6) cells were obtained from the American Type Culture Collection  
264 (ATCC). C7/10 cells were maintained in Dulbecco's minimal essential medium  
265 (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% minimal essential  
266 medium non-essential amino acids, 1% tryptose phosphate broth and 0.05 mg/mL  
267 gentamycin in a 30°C incubator with 5% CO<sub>2</sub>. Vero cells were maintained in DMEM  
268 supplemented with 10% FBS and 0.05 mg/mL gentamycin in a 37°C incubator with  
269 5% CO<sub>2</sub>.

270 NEGV was rescued in C7/10 cells from an infectious clone as previously  
271 described and without further passage (47). The sequence was derived from NEGV  
272 strain M30957 isolated from a pool of *Culex coronator* mosquitoes collected in  
273 Harris County, Texas, USA in 2008 (17). Piura virus (PIUV) strain EVG 7-47 (PIUV-  
274 *Culex*) isolated from a pool of *Culex nigripalpus* mosquitoes from Everglades  
275 National Park, Florida, USA in 2013 (22). PIUV EVG 7-47 was passaged four times in  
276 C6/36 cells and obtained from the WRCEVA. PIUV strain CO R 10 (PIUV-Lutzomyia)

277 was isolated from a pool of *Lutzomyia evansi* sandflies caught in Ovejas, Sucre,  
278 Colombia in 2013 (22). The isolate PIUV CO R 10 was passaged twice in C6/36 cells  
279 and also obtained from the WRCEVA. CHIKV isolate 181/25 (48) was rescued in  
280 Vero cells from an infectious clone as previously described (49). Rescued CHIKV  
281 181/25 was subsequently passaged once in C7/10 cells and once in Vero cells.  
282 Venezuelan equine encephalitis virus (VEEV) vaccine strain, TC-83 (50), was  
283 rescued in baby hamster kidney (BHK) cells from an infectious clone without  
284 further passage. VEEV isolate P676 (VEEV-IC), and SFV isolate A774/C2/A were  
285 attained from Public Health England and passaged once in Vero cells. ONNV isolate  
286 UgMP30, and Mayaro virus (MAYV) isolates Guyane, BeAn344102, and BeAr505411  
287 were attained from BEI Resources and passaged once in Vero cells.

288

#### 289 *Cloning NEGV for exogenous gene expression*

290 The NEGV infectious clone was used as the backbone to express exogenous  
291 genes. Green fluorescent protein (GFP; 717bp) was inserted along several sites of  
292 the NEGV genome and the single chain variable fragment (scFv) of anti-CHIKV  
293 neutralizing antibody CHK265 (771bp including linkers) (39) was inserted on the C-  
294 terminal of ORF3 as either a fusion protein, or with a 2A sequence  
295 (EGRGSLLTCDVEENPGP) (Figure 1A). The cloned scFv CHK265 sequence  
296 contained a N-terminal linker (LAAQPAMA) for articulation from the viral ORF3  
297 protein, and a domain linker ((G<sub>4</sub>S)<sub>4</sub>) between the variable heavy (V<sub>H</sub>) and variable  
298 light (V<sub>L</sub>) domains (Integrative DNA Technologies) (Figure 1B). Cloning was  
299 performed using In-Fusion HD Cloning Kit (Takara Bio) as per the manufacturer's

300 protocol. Correct insertion was confirmed by sequencing. Infectious clones of NEG V  
301 containing exogenous genes were rescued in C7/10 cells as previously described  
302 and without further passage (47). Passaging of NEG V isolates expressing GFP was  
303 performed by inoculating C7/10 cells with a MOI of 1 and collecting media  
304 supernatant at 48 hours post infection.

305

#### 306 *Virus growth curves*

307 Negevirus and alphavirus growth curves were done in C7/10 cells  
308 maintained at 30°C and 5% CO<sub>2</sub>. Negevirus were inoculated at a multiplicity of  
309 infection (MOI) of 1 or 5. Alphaviruses were inoculated at a MOI of 0.1. Virus was  
310 added to the cells which were incubated at 30°C for one hour. Inoculum was  
311 removed, cells were washed with PBS, and fresh media was added to the wells. Cells  
312 were incubated in a 30°C incubator with 5% CO<sub>2</sub>. Samples were collected in  
313 triplicate at 2-, 6-, 12-, 24- and 48-hours post infection (hpi). Samples were clarified  
314 by centrifugation at 1962 *x g* for 5 minutes. Supernatant was removed and stored at  
315 -80°C until used for plaque assays. Negevirus titers were determined by plaque  
316 assay in C7/10 cells as previously described (47). Alphavirus titers were  
317 determined by standard plaque assay in Vero cells.

318

#### 319 *Negevirus-alphavirus co-infections*

320 C7/10 cells were inoculated with negevirus isolates at a MOI of 1 or 5 to  
321 establish infection in a high proportion of cells. The cells were also inoculated with  
322 an alphavirus at a MOI of 0.1 at 0, 2, or 6 hours post negevirus infection. Media was

323 removed after 1 hour of simultaneous incubation with negevirus and alphavirus  
324 inocula. Cells were then washed with PBS, and fresh medium was added to the wells.  
325 Cells were held in a 30°C incubator with 5% CO<sub>2</sub>. Samples were collected in  
326 triplicate at 12-, 24- and 48-hours, or 24- and 48-hours post alphavirus infection.  
327 Samples were clarified by centrifugation at 1962 *x g* for 5 minutes. Supernatant was  
328 removed and stored at -80°C until used for plaque assays. Alphavirus titers were  
329 determined by standard plaque assay in Vero cells.

330

### 331 *Statistical analysis*

332 Differences in virus growth curves were determined by two-way ANOVA  
333 followed by Tukey's test. Comparison of NEGV growth curves with different MOIs  
334 was determined by multiple t tests followed by Holm-Sidak method. All statistical  
335 tests were performed using GraphPad Prism 6.0.

336

### 337 **Acknowledgements**

338 EIP was supported by the Liverpool School of Tropical Medicine Director's Catalyst  
339 Fund award. NLF was supported by the NIH R01-AI095753-01A1 and R01-  
340 AI125902. GLH was supported by the BBSRC (BB/T001240/1 and V011278/1), a  
341 Royal Society Wolfson Fellowship (RSWF\R1\180013), the NIH (R21AI138074),  
342 URKI (20197), and the NIHR (NIHR2000907). GLH is affiliated to the National  
343 Institute for Health Research Health Protection Research Unit (NIHR HPRU) in  
344 Emerging and Zoonotic Infections at University of Liverpool in partnership with  
345 Public Health England (PHE), in collaboration with Liverpool School of Tropical

346 Medicine and the University of Oxford. GLH is based at LSTM. The views expressed  
347 are those of the author(s) and not necessarily those of the NHS, the NIHR, the  
348 Department of Health or Public Health England.

349

#### 350 **Author Contributions**

351 EIP designed the experiments. EIP, TK, MAC-G and HG completed the experiments.  
352 EIP undertook analysis. EIP, TK, RBT, GLH and NLF wrote and edited the manuscript  
353 and all authors agreed to the final version. RBT, GLH and NLF provided supervision.  
354 EIP and NLF acquired the funding.

355

#### 356 **References**

357

358 1. **Calisher CH, Higgs S.** 2018. The Discovery of Arthropod-Specific Viruses in  
359 Hematophagous Arthropods: An Open Door to Understanding the  
360 Mechanisms of Arbovirus and Arthropod Evolution? *Annu Rev Entomol*  
361 **63**:87-103.

362 2. **Ledermann JP, Suchman EL, Black WCt, Carlson JO.** 2004. Infection and  
363 pathogenicity of the mosquito densoviruses AeDNV, HeDNV, and APeDNV in  
364 *Aedes aegypti* mosquitoes (Diptera: Culicidae). *J Econ Entomol* **97**:1828-  
365 1835.

366 3. **Carlson J, Suchman E, Buchatsky L.** 2006. Densoviruses for control and  
367 genetic manipulation of mosquitoes. *Adv Virus Res* **68**:361-392.

- 368 4. **Hirunkanokpun S, Carlson JO, Kittayapong P.** 2008. Evaluation of  
369 mosquito densoviruses for controlling *Aedes aegypti* (Diptera: Culicidae):  
370 variation in efficiency due to virus strain and geographic origin of  
371 mosquitoes. *Am J Trop Med Hyg* **78**:784-790.
- 372 5. **Baidaliuk A, Miot EF, Lequime S, Moltini-Conclois I, Delaigue F, Dabo S,**  
373 **Dickson LB, Aubry F, Merklings SH, Cao-Lormeau VM, Lambrechts L.**  
374 2019. Cell-Fusing Agent Virus Reduces Arbovirus Dissemination in *Aedes*  
375 *aegypti* Mosquitoes In Vivo. *J Virol* **93**.
- 376 6. **Goenaga S, Kenney JL, Duggal NK, Delorey M, Ebel GD, Zhang B, Levis SC,**  
377 **Enria DA, Brault AC.** 2015. Potential for Co-Infection of a Mosquito-Specific  
378 Flavivirus, Nhumirim Virus, to Block West Nile Virus Transmission in  
379 Mosquitoes. *Viruses* **7**:5801-5812.
- 380 7. **Hall-Mendelin S, McLean BJ, Bielefeldt-Ohmann H, Hobson-Peters J, Hall**  
381 **RA, van den Hurk AF.** 2016. The insect-specific Palm Creek virus modulates  
382 West Nile virus infection in and transmission by Australian mosquitoes.  
383 *Parasit Vectors* **9**:414.
- 384 8. **Hobson-Peters J, Yam AW, Lu JW, Setoh YX, May FJ, Kurucz N, Walsh S,**  
385 **Prow NA, Davis SS, Weir R, Melville L, Hunt N, Webb RI, Blitvich BJ,**  
386 **Whelan P, Hall RA.** 2013. A new insect-specific flavivirus from northern

- 387 Australia suppresses replication of West Nile virus and Murray Valley  
388 encephalitis virus in co-infected mosquito cells. PLoS One **8**:e56534.
- 389 9. **Kenney JL, Solberg OD, Langevin SA, Brault AC.** 2014. Characterization of a  
390 novel insect-specific flavivirus from Brazil: potential for inhibition of  
391 infection of arthropod cells with medically important flaviviruses. J Gen Virol  
392 **95**:2796-2808.
- 393 10. **Romo H, Kenney JL, Blitvich BJ, Brault AC.** 2018. Restriction of Zika virus  
394 infection and transmission in *Aedes aegypti* mediated by an insect-specific  
395 flavivirus. Emerg Microbes Infect **7**:181.
- 396 11. **Nasar F, Erasmus JH, Haddow AD, Tesh RB, Weaver SC.** 2015. Eilat virus  
397 induces both homologous and heterologous interference. Virology **484**:51-  
398 58.
- 399 12. **Burivong P, Pattanakitsakul SN, Thongrungrat S, Malasit P, Flegel TW.**  
400 2004. Markedly reduced severity of Dengue virus infection in mosquito cell  
401 cultures persistently infected with *Aedes albopictus* densovirus (AalDNV).  
402 Virology **329**:261-269.
- 403 13. **Schultz MJ, Frydman HM, Connor JH.** 2018. Dual Insect specific virus  
404 infection limits Arbovirus replication in *Aedes* mosquito cells. Virology  
405 **518**:406-413.

- 406 14. **Ye G, Wang Y, Liu X, Dong Q, Cai Q, Yuan Z, Xia H.** 2020. Transmission  
407 competence of a new mesonivirus, Yichang virus, in mosquitoes and its  
408 interference with representative flaviviruses. *PLoS Negl Trop Dis*  
409 **14:e0008920.**
- 410 15. **Zhang G, Asad S, Khromykh AA, Asgari S.** 2017. Cell fusing agent virus and  
411 dengue virus mutually interact in *Aedes aegypti* cell lines. *Sci Rep* **7:6935.**
- 412 16. **Bolling BG, Olea-Popelka FJ, Eisen L, Moore CG, Blair CD.** 2012.  
413 Transmission dynamics of an insect-specific flavivirus in a naturally infected  
414 *Culex pipiens* laboratory colony and effects of co-infection on vector  
415 competence for West Nile virus. *Virology* **427:90-97.**
- 416 17. **Vasilakis N, Forrester NL, Palacios G, Nasar F, Savji N, Rossi SL, Guzman**  
417 **H, Wood TG, Popov V, Gorchakov R, Gonzalez AV, Haddow AD, Watts DM,**  
418 **da Rosa AP, Weaver SC, Lipkin WI, Tesh RB.** 2013. Negevirus: a proposed  
419 new taxon of insect-specific viruses with wide geographic distribution. *J Virol*  
420 **87:2475-2488.**
- 421 18. **Carapeta S, do Bem B, McGuinness J, Esteves A, Abecasis A, Lopes A, de**  
422 **Matos AP, Piedade J, de Almeida AP, Parreira R.** 2015. Negevirus found  
423 in multiple species of mosquitoes from southern Portugal: Isolation, genetic  
424 diversity, and replication in insect cell culture. *Virology* **483:318-328.**

- 425 19. **Charles J, Tangudu CS, Hurt SL, Tumescheit C, Firth AE, Garcia-Rejon JE,**  
426 **Machain-Williams C, Blitvich BJ.** 2018. Detection of novel and recognized  
427 RNA viruses in mosquitoes from the Yucatan Peninsula of Mexico using  
428 metagenomics and characterization of their in vitro host ranges. *J Gen Virol*  
429 **99:1729-1738.**
- 430 20. **Kondo H, Chiba S, Maruyama K, Andika IB, Suzuki N.** 2019. A novel insect-  
431 infecting virga/nege-like virus group and its pervasive endogenization into  
432 insect genomes. *Virus Res* **262:37-47.**
- 433 21. **Kondo H, Fujita M, Hisano H, Hyodo K, Andika IB, Suzuki N.** 2020. Virome  
434 Analysis of Aphid Populations That Infest the Barley Field: The Discovery of  
435 Two Novel Groups of Nege/Kita-Like Viruses and Other Novel RNA Viruses.  
436 *Front Microbiol* **11:509.**
- 437 22. **Nunes MRT, Contreras-Gutierrez MA, Guzman H, Martins LC, Barbirato**  
438 **MF, Savit C, Balta V, Uribe S, Vivero R, Suaza JD, Oliveira H, Nunes Neto**  
439 **JP, Carvalho VL, da Silva SP, Cardoso JF, de Oliveira RS, da Silva Lemos P,**  
440 **Wood TG, Widen SG, Vasconcelos PFC, Fish D, Vasilakis N, Tesh RB.** 2017.  
441 Genetic characterization, molecular epidemiology, and phylogenetic  
442 relationships of insect-specific viruses in the taxon Negevirus. *Virology*  
443 **504:152-167.**

- 444 23. **De Miranda JRH, H.; Onorati, P.; Stephan, J.; Karlberg, O.; Bylund, H.;**  
445 **Terenius, O.** 2017. Characterization of a Novel RNA Virus Discovered in the  
446 Autumnal Moth *Epirrita autumnata* in Sweden. *Viruses* **9**.
- 447 24. **Kallies R, Kopp A, Zirkel F, Estrada A, Gillespie TR, Drosten C, Junglen S.**  
448 2014. Genetic characterization of goutanap virus, a novel virus related to  
449 negeviruses, cileviruses and higreviruses. *Viruses* **6**:4346-4357.
- 450 25. **Lu G, Ye ZX, He YJ, Zhang Y, Wang X, Huang HJ, Zhuo JC, Sun ZT, Yan F,**  
451 **Chen JP, Zhang CX, Li JM.** 2020. Discovery of Two Novel Negeviruses in a  
452 Dungfly Collected from the Arctic. *Viruses* **12**.
- 453 26. **Colmant AMG, O'Brien CA, Newton ND, Watterson D, Hardy J, Coulibaly**  
454 **F, Bielefeldt-Ohmann H, Warrilow D, Huang B, Paramitha D, Harrison JJ,**  
455 **Hall RA, Hobson-Peters J.** 2020. Novel monoclonal antibodies against  
456 Australian strains of negeviruses and insights into virus structure, replication  
457 and host -restriction. *J Gen Virol* **101**:440-452.
- 458 27. **Nabeshima T, Inoue S, Okamoto K, Posadas-Herrera G, Yu F, Uchida L,**  
459 **Ichinose A, Sakaguchi M, Sunahara T, Buerano CC, Tadena FP, Orbita IB,**  
460 **Natividad FF, Morita K.** 2014. Tanay virus, a new species of virus isolated  
461 from mosquitoes in the Philippines. *J Gen Virol* **95**:1390-1395.

- 462 28. **O'Brien CA, McLean BJ, Colmant AMG, Harrison JJ, Hall-Mendelin S, van**  
463 **den Hurk AF, Johansen CA, Watterson D, Bielefeldt-Ohmann H, Newton**  
464 **ND, Schulz BL, Hall RA, Hobson-Peters J.** 2017. Discovery and  
465 Characterisation of Castlerea Virus, a New Species of Negevirus Isolated in  
466 Australia. *Evol Bioinform Online* **13**:1176934317691269.
- 467 29. **Shi M, Neville P, Nicholson J, Eden JS, Imrie A, Holmes EC.** 2017. High-  
468 Resolution Metatranscriptomics Reveals the Ecological Dynamics of  
469 Mosquito-Associated RNA Viruses in Western Australia. *J Virol* **91**.
- 470 30. **Atoni E, Wang Y, Karungu S, Waruhiu C, Zohaib A, Obanda V, Agwanda B,**  
471 **Mutua M, Xia H, Yuan Z.** 2018. Metagenomic Virome Analysis of Culex  
472 Mosquitoes from Kenya and China. *Viruses* **10**.
- 473 31. **Cross ST, Kapuscinski ML, Perino J, Maertens BL, Weger-Lucarelli J, Ebel**  
474 **GD, Stenglein MD.** 2018. Co-Infection Patterns in Individual Ixodes  
475 scapularis Ticks Reveal Associations between Viral, Eukaryotic and Bacterial  
476 Microorganisms. *Viruses* **10**.
- 477 32. **Hegde S, Khanipov K, Albayrak L, Golovko G, Pimenova M, Saldana MA,**  
478 **Rojas MM, Hornett EA, Motl GC, Fredregill CL, Dennett JA, Debboun M,**  
479 **Fofanov Y, Hughes GL.** 2018. Microbiome Interaction Networks and  
480 Community Structure From Laboratory-Reared and Field-Collected Aedes

- 481 aegypti, Aedes albopictus, and Culex quinquefasciatus Mosquito Vectors.  
482 Front Microbiol **9**:2160.
- 483 33. **Nanfack-Minkeu F, Mitri C, Bischoff E, Belda E, Casademont I, Vernick**  
484 **KD.** 2019. Interaction of RNA viruses of the natural virome with the African  
485 malaria vector, Anopheles coluzzii. Sci Rep **9**:6319.
- 486 34. **Kuwata R, Isawa H, Hoshino K, Sasaki T, Kobayashi M, Maeda K, Sawabe**  
487 **K.** 2015. Analysis of Mosquito-Borne Flavivirus Superinfection in Culex  
488 tritaeniorhynchus (Diptera: Culicidae) Cells Persistently Infected with Culex  
489 Flavivirus (Flaviviridae). J Med Entomol **52**:222-229.
- 490 35. **Newman CM, Krebs BL, Anderson TK, Hamer GL, Ruiz MO, Brawn JD,**  
491 **Brown WM, Kitron UD, Goldberg TL.** 2017. Culex Flavivirus During West  
492 Nile Virus Epidemic and Interepidemic Years in Chicago, United States.  
493 Vector Borne Zoonotic Dis **17**:567-575.
- 494 36. **Talavera S, Birnberg L, Nunez AI, Munoz-Munoz F, Vazquez A, Busquets**  
495 **N.** 2018. Culex flavivirus infection in a Culex pipiens mosquito colony and its  
496 effects on vector competence for Rift Valley fever phlebovirus. Parasit  
497 Vectors **11**:310.

- 498 37. **Kent RJ, Crabtree MB, Miller BR.** 2010. Transmission of West Nile virus by  
499 Culex quinquefasciatus say infected with Culex Flavivirus Izabal. PLoS Negl  
500 Trop Dis **4**:e671.
- 501 38. **Patterson EI, Villinger J, Muthoni JN, Dobel-Ober L, Hughes GL.** 2020.  
502 Exploiting insect-specific viruses as a novel strategy to control vector-borne  
503 disease. Curr Opin Insect Sci **39**:50-56.
- 504 39. **Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle**  
505 **KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE, Jr., Fremont DH,**  
506 **Rossmann MG, Diamond MS.** 2015. Broadly Neutralizing Alphavirus  
507 Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Cell  
508 **163**:1095-1107.
- 509 40. **Jiggins FM.** 2017. The spread of Wolbachia through mosquito populations.  
510 PLoS Biol **15**:e2002780.
- 511 41. **Gantz VM, Jasinskiene N, Tatarenkova O, Fazekas A, Macias VM, Bier E,**  
512 **James AA.** 2015. Highly efficient Cas9-mediated gene drive for population  
513 modification of the malaria vector mosquito Anopheles stephensi. Proc Natl  
514 Acad Sci U S A **112**:E6736-6743.
- 515 42. **Buchman A, Gamez S, Li M, Antoshechkin I, Li HH, Wang HW, Chen CH,**  
516 **Klein MJ, Duchemin JB, Crowe JE, Jr., Paradkar PN, Akbari OS.** 2020.

- 517 Broad dengue neutralization in mosquitoes expressing an engineered  
518 antibody. PLoS Pathog **16**:e1008103.
- 519 43. **Kawakami K, Kurnia YW, Fujita R, Ito T, Isawa H, Asano S, Binh ND,**  
520 **Bando H.** 2016. Characterization of a novel negevirus isolated from Aedes  
521 larvae collected in a subarctic region of Japan. Arch Virol **161**:801-809.
- 522 44. **Kautz TF, Jaworski E, Routh A, Forrester NL.** 2020. A Low Fidelity Virus  
523 Shows Increased Recombination during the Removal of an Alphavirus  
524 Reporter Gene. Viruses **12**.
- 525 45. **Suzuki Y, Niu G, Hughes GL, Rasgon JL.** 2014. A viral over-expression  
526 system for the major malaria mosquito Anopheles gambiae. Sci Rep **4**:5127.
- 527 46. **Walker T, Jeffries CL, Mansfield KL, Johnson N.** 2014. Mosquito cell lines:  
528 history, isolation, availability and application to assess the threat of arboviral  
529 transmission in the United Kingdom. Parasit Vectors **7**:382.
- 530 47. **Gorchakov RV, Tesh RB, Weaver SC, Nasar F.** 2014. Generation of an  
531 infectious Negev virus cDNA clone. J Gen Virol **95**:2071-2074.
- 532 48. **Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Jr., Lupton HW.**  
533 1986. Development of an attenuated strain of chikungunya virus for use in  
534 vaccine production. Vaccine **4**:157-162.

535 49. **Smith DR, Adams AP, Kenney JL, Wang E, Weaver SC.** 2008. Venezuelan  
536 equine encephalitis virus in the mosquito vector *Aedes taeniorhynchus*:  
537 infection initiated by a small number of susceptible epithelial cells and a  
538 population bottleneck. *Virology* **372**:176-186.

539 50. **Kinney RM, Chang GJ, Tsuchiya KR, Sneider JM, Roehrig JT, Woodward**  
540 **TM, Trent DW.** 1993. Attenuation of Venezuelan equine encephalitis virus  
541 strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope  
542 glycoprotein. *J Virol* **67**:1269-1277.

543

544

545

546

#### 547 **Figure legends**

548 Figure 1. Growth curve for wild-type negevirus. A) The titer of each virus, Negev  
549 virus (NEGV), Piura virus-Culex (PIUV-Culex) and Piura virus-Lutzomyia (PIUV-  
550 Lutzomyia) at different time points following infection at MOI of 1 in C7/10 cells. B)  
551 Growth curve of NEGV with MOI of 1 and 5 in C7/10 cells. All points represent mean  
552 of n=3,  $\pm$  SD. Letters indicate significant differences ( $p < 0.0001$ ).

553

554 Figure 2. Growth curves of VEEV-TC83 in C7/10 cells during co-infections with wild-  
555 type negevirus. A) Growth curves of VEEV-TC83 when inoculated on cells at 0-, 2-  
556 and 6 hours post NEGV infections. NEGV was inoculated at MOI 1 or 5. B) Growth

557 curves of VEEV-TC83 when inoculated on cells at 0 hours post negevirus infection,  
558 C) 2 hours post negevirus infection, and D) 6 hours post negevirus infection.  
559 Negevirus were inoculated at MOI of 1 (B-D). VEEV-TC83 was inoculated at a MOI  
560 of 0.1 in all conditions. All points represent mean of  $n=3$ ,  $\pm$  SD. Letters indicate  
561 significant differences ( $p < 0.0001$ ).

562

563 Figure 3. Growth curves of CHIKV in C7/10 cells during co-infections with wild-type  
564 negevirus. A) Growth curves of CHIKV when inoculated on cells at 0-, 2- and 6  
565 hours post NEGV infections. NEGV was inoculated at MOI 1 or 5. B) Growth curves of  
566 CHIKV when inoculated on cells at 0 hours post negevirus infection, C) 2 hours post  
567 negevirus infection, and D) 6 hours post negevirus infection. Negevirus were  
568 inoculated at MOI of 1 (B-D). CHIKV was inoculated at a MOI of 0.1 in all conditions.  
569 All points represent mean of  $n=3$ ,  $\pm$  SD. Letters indicate significant differences ( $p <$   
570  $0.0001$ ).

571

572 Figure 4. Growth curves of VEEV-IC, MAYV isolates, ONNV, and SFV in C7/10 cells  
573 during co-infections with wild-type negevirus. A) Growth curves of VEEV-IC when  
574 inoculated on cells at 0 hours post negevirus infections. B) Growth curves of MAYV-  
575 Guyane, MAYV-BeAn343102, and MAYV-BeAr505411 when inoculated on cells at 0  
576 hours post negevirus infection. C) Growth curves of ONNV when inoculated on cells  
577 at 0 hours post negevirus infection. D) Growth curves of SFV when inoculated on  
578 cells at 0 hours post negevirus infection. Negevirus were inoculated at MOI of 1 in  
579 all conditions. Alphaviruses were inoculated at a MOI of 0.1 in all conditions. All

580 points represent mean of  $n=3$ ,  $\pm$  SD. Letters indicate significant differences ( $p <$   
581  $0.0001$ ).

582

583 Figure 5. Rescued paratransgenic NEGV infectious clones. A) Schematic of NEGV  
584 genomes for wild-type, and GFP-expressing viruses. NEGV GFP-fusion added the  
585 GFP sequence onto ORF3 and NEGV GFP separated the ORF3 and GFP with a 2A  
586 sequence to produce the proteins separately. GFP was replaced by scFv-CHK265 for  
587 NEGV scFv-CHK265-fusion and NEGV scFv-CHK265. B) Growth curves of NEGV  
588 wild-type and NEGV mutants expressing GFP or scFv-CHK265. All points represent  
589 mean of  $n=3$ ,  $\pm$  SD. Letters indicate significant differences ( $p < 0.0001$ ). C)  
590 Fluorescent microscopy of C7/10 cells infected with NEGV GFP-fusion. Cells  
591 demonstrate brilliant, punctate fluorescence. D) Fluorescent microscopy of C7/10  
592 cells infected with NEGV GFP. Cells demonstrate dull, diffuse fluorescence. E) The  
593 ratio of plaques to fluorescent plaques over 5 passages in C7/10 cells with NEGV  
594 GFP-fusion and NEGV GFP. All points represent mean of  $n=3$ ,  $\pm$  SD. F) Titer of NEGV  
595 GFP-fusion and NEGV GFP during 5 passages in C7/10 cells. All points represent  
596 mean of  $n=3$ ,  $\pm$  SD. All NEGV isolates were inoculated at MOI of 1.

597

598 Figure 6. Growth curves of VEEV-TC83 during co-infections with paratransgenic  
599 NEGV. Growth curves of VEEV-TC83 when inoculated on cells at A) 0 hours post  
600 NEGV infection, B) 2 hours post NEGV infection, and C) 6 hours post NEGV infection.  
601 All NEGV isolates were inoculated at MOI of 1. VEEV-TC83 was inoculated at a MOI

602 of 0.1 in all conditions. All points represent mean of  $n=3$ ,  $\pm$  SD. Letters indicate  
603 significant differences ( $p < 0.0001$ ).

604

605 Figure 7. Growth curves of CHIKV during co-infections with paratransgenic NEGV.

606 Growth curves of CHIKV when inoculated on cells at A) 0 hours post NEGV infection,

607 B) 2 hours post NEGV infection, and C) 6 hours post NEGV infection. All NEGV

608 isolates were inoculated at MOI of 1. CHIKV was inoculated at a MOI of 0.1 in all

609 conditions. All points represent mean of  $n=3$ ,  $\pm$  SD. Letters indicate significant


610 differences ( $p < 0.0001$ ).

611 **Tables**

612 Table 1. Rescue and passage of NEGV infectious clones with GFP inserted at different  
613 sites of the genome. Transcribed RNA was electroporated for P0 stock and  
614 supernatant was collected to generate P1 stock.

Insertion site	GFP expression P0	GFP expression P1	CPE
ORF1-2A-GFP	+	+	+
GFP-ORF2	+	-	-
ORF2-GFP	+	-	-
ORF2-2A-GFP	+	-	-
GFP-ORF3	+	-	-
ORF3-GFP	+	+	+
ORF3-2A-GFP	+	+	+


615

616 **Figures**

617

618 Figure 1.


619



620

621 Figure 2.


622



623

624 Figure 3.


625



626

627 Figure 4.


628



629

630 Figure 5.


631



632

633 Figure 6.

634



635

636 Figure 7.